It cannot currently be prescribed, dispensed or supplied as a licensed weight loss treatment in the UK
What's underlying the fight, says Robin Feldman, a law professor at the University of California, is "the inordinate amount of money that is changing hands for the new weight-loss drugs, their incredible efficacy, the runaway demand
Tsai WH, Sung FC, Chiu LT, Shih YH, Tsai MC, Wu SI
marketed for diabetes as Mounjaro and for weight management under trade names such as Zepbound) Tirzepatide combines GLP-1 and GIP receptor agonism and has shown the largest average weight losses of any medication to date
Evidence, Safety, and the Regulatory Landscape GLP-1 microdosing is biologically plausible, but its safety and effectiveness have not been validated in randomized clinical trials
It has a stronger and longer-lasting action in the body, enabling a higher dosage to result in more weight reduction